Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel
Recruiting in Palo Alto (17 mi)
+10 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Adaptimmune
No Placebo Group
Trial Summary
What is the purpose of this trial?
The purpose of this expanded access protocol (EAP) is to provide controlled access to Afamitresgene autoleucel, suspension for intravenous infusion that does not meet the commercial release specification (NC afami-cel). This EAP will be conducted at authorized treatment centers where TECELRA® is being administered and where the EAP is approved to be conducted. Patients who are prescribed TECELRA® , sign the informed consent form, and meet all entry criteria will be eligible to participate in this protocol.
Research Team
Eligibility Criteria
Inclusion Criteria
I have signed a consent form to participate in this study.
My medication does not meet its standard quality requirements.
A second leukapheresis is not possible or suitable for me according to my doctor.
See 5 more
Treatment Details
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Mayo ArizonaPhoenix, AZ
Moffit Cancer CenterTampa, FL
Northwestern University Feinberg School of MedicineChicago, IL
Memorial Sloan Kettering Cancer CentreNew York, NY
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Adaptimmune
Lead Sponsor
Trials
25
Patients Recruited
10,000+